European Society for Blood and Marrow Transplantation (EBMT), 2023


  1. OVERALL SURVIVAL OF BREXU-CEL (ZUMA-2) AND STANDARD OF CARE (SCHOLAR-2) IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PREVIOUSLY TREATED WITH A BRUTON TYROSINE KINASE INHIBITOR
  2. 3-YEAR FOLLOW-UP ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)
  3. OUTCOMES OF SUBSEQUENT ANTI-LYMPHOMA THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) OR STANDARD OF CARE (SOC; ZUMA-7)
  4. SUBGROUP ANALYSES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL), AN ANTI-CD19 CAR T-CELL THERAPY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3
  5. ASSOCIATION OF METABOLIC TUMOR VOLUME (MTV) AND CLINICAL OUTCOMES IN SECOND-LINE RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA FOLLOWING AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS STANDARD-OF-CARE (SOC) THERAPY IN ZUMA-7
  6. PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): 2-YEAR FOLLOW-UP OF ZUMA-1 COHORT 6
  7. COMMERCIAL MANUFACTURING EXPERIENCE OF AXICABTAGENE CILOLEUCEL DELIVERY IN EUROPE: FROM THE FIRST 2 YEARS TO THE LATEST 2 YEARS